RJ Barst, LJ Rubin, WA Long, MD McGoon, S … - New England Journal of Medicine, 1996 - content.nejm.org Hemodynamics improved at 12 weeks in the epoprostenol-treated patients. The
changes in mean pulmonary-artery pressure for the epoprostenol and control
groups were -8 percent and +3 percent, respectively (difference in mean ... Cited by 1406 - Related articles - BL Direct - All 9 versions
- ►chestpubs.org [PDF] LJ Rubin - The New England journal of medicine, 1997 - nejm.highwire.org Estimates of the incidence of primary pulmonary hypertension range from 1 to 2
cases per million people in the general population. 6 , 7 The incidence of
pulmonary vascular disease in patients with other illnesses is not known, ... Cited by 1069 - Related articles - BL Direct - All 18 versions
H Olschewski, G Simonneau, N Galie, T … - New England Journal of Medicine, 2002 - content.nejm.org Methods We compared repeated daily inhalations of 2.5 or 5.0 µg of iloprost
(six or nine times per day; median inhaled dose, 30 µg per day) with inhalation
of placebo. A total of 203 patients with selected forms of severe pulmonary ... Cited by 852 - Related articles - BL Direct - All 19 versions
- ►annals.org [PDF] DB Badesch, VF Tapson, MD McGoon, BH … - Annals of Internal Medicine, 2000 - Am Coll Physicians David B. Badesch, MD; Victor F. Tapson, MD; Michael D. McGoon, MD; Bruce H.
Brundage, MD; Lewis J. Rubin, MD; Fredrick M. Wigley, MD; Stuart Rich, MD; Robyn
J. Barst, MD; Pamela S. Barrett, PharmD; Kenneth M. Kral, MS; Maria M. ... Cited by 649 - Related articles - BL Direct - All 6 versions
VV McLaughlin, DE Genthner, MM Panella, S … - The New England journal of medicine, 1998 - nejm.highwire.org Results We evaluated 27 patients with primary pulmonary hypertension over a mean
(±SD) period of 16.7±5.2 months. Intravenous adenosine had a variable effect
on pulmonary vascular resistance (mean reduction, 27 percent; range, 0 to ... Cited by 550 - Related articles - BL Direct - All 7 versions
- ►utmem.edu [PDF] MM Hoeper, M Schwarze, S Ehlerding, A … - New England Journal of Medicine, 2000 - content.nejm.org Results Twenty-four patients with primary pulmonary hypertension received
aerosolized iloprost at a daily dose of 100 or 150 µg for at least one year.
The mean (±SD) distance covered in the six-minute walk test increased from ... Cited by 459 - Related articles - BL Direct - All 11 versions
- ►phcentral.org [PDF] SP Gaine, LJ Rubin - The Lancet, 1998 - Elsevier Primary pulmonary hypertension (PPH) is a progressive disease characterised by
raised pulmonary vascular resistance, which results in diminished right-heart
function due to increased right ventricular afterload. PPH occurs most ... Cited by 379 - Related articles - BL Direct - All 7 versions
- ►annals.org H Olschewski, D Walmrath, R Schermuly, HA … - Annals of internal medicine, 1996 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Objective: To compare the effects of aerosolization of prostacyclin and its ... Cited by 344 - Related articles - All 5 versions
- ►westhertshospitals.nhs.uk [PDF] JR Runo, JE Loyd - The Lancet, 2003 - Elsevier Primary pulmonary hypertension (PPH) is a rare disorder characterised by raised
pulmonary-artery pressure in the absence of secondary causes. Precapillary
pulmonary arteries are affected by medial hypertrophy, intimal fibrosis, ... Cited by 301 - Related articles - All 13 versions
RM Califf, KF Adams, WJ McKenna, M … - American heart journal, 1997 - Elsevier Studies developing the methods of continuous home infusion of a vasoactive
substance have demonstrated a substantial improvement in exercise tolerance and
survival in patients with primary pulmonary hypertension treated with ... Cited by 293 - Related articles - BL Direct - All 7 versions
